Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05775016
Other study ID # IRB-23-29
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 29, 2023
Est. completion date March 15, 2024

Study information

Verified date May 2023
Source Lindenwood University
Contact Anthony M Hagele, MS
Phone 636-949-4785
Email ahagele@lindenwood.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Beta-amino isobutyric acid (BAIBA) is a myokine produced in skeletal muscle and has been shown to impact how our body metabolizes fuel. We seek to examine changes in body composition, weight loss, glucose control, and cardiometabolic risk factors after adding supplementation of BAIBA to exercise in overweight and obese men and women.


Description:

This study will be conducted using a double-blind, placebo-controlled, parallel group design. Eligible study participants will be randomly assigned to one of three supplementation groups: placebo (resistant dextrin) supplementation + exercise group, 750 mg BAIBA supplementation + exercise group, and a 1500 mg BAIBA supplementation + exercise group. After signing an IRB-approved consent form, prospective participants will be scheduled for a screening visit where they will have their eligibility finalized through completion of a peak VO2 assessment using a motorized treadmill and metabolic cart. Eligible participants will then be fully explained the study and scheduled for a baseline testing session (week 0). Prior to scheduling this visit, participants must complete a 4-day food record. Once a food record is completed, participants will observe an overnight fast and be scheduled to complete the testing session between the hours of 0600 - 1000 hours. Upon arrival, changes in medical status, medications, and dietary supplements will be confirmed before having their body mass and hemodynamics assessed. Next, participants will have their waist circumference, body water (BIS), and body composition (DEXA) assessed to evaluate changes in body composition and obesity status throughout the study protocol. Participants will then have a venous blood sample collected for evaluation of health markers (complete blood counts, comprehensive metabolic panels, and lipid panels) before completing a resting metabolic rate measurement. The resting metabolic rate measurement will be used to prescribe energy intake throughout the study protocol. Participants will then use an electronic tablet and complete the Profile of Mood States and visual analog scales to evaluate perceptions of hunger and appetite. Participants will then be given their first daily dose. All participants will be given instructions and meal plans as well as be offered weekly educational sessions on how to restrict calories and meet protein goals throughout the study protocol. Participants will complete five days per week of exercise consisting of a mixture of walking and resistance training. Daily compliance to the exercise and supplementation groups will be monitored weekly for a 12-week period. Participants who complete at least 80% of their assigned workouts will be considered compliant and will be scheduled for follow-up visits after 6 and 12 weeks of supplementation.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date March 15, 2024
Est. primary completion date March 15, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Participants who are between 18 - 60 years of age - Body mass index values will range from >25.0 to < 32.0 kg/m2, making them qualified as an overweight-to-obese population (https://www.nhlbi.nih.gov/health/educational/lose_wt/BMI/bmicalc.htm) - Average body mass index for entire study cohort will be less than 30.0 kg/m2. As such an ongoing calculation of the recruited cohort's mean body mass index will be maintained and people will only be randomized into the study if the average cohort body mass index value does not exceed 30.0 kg/m2 - Free-living/uninhibited with use of ambulatory assistive devices (e.g. canes, crutches, walkers, etc.) and independent - In good health absent of being overweight or mildly obese with no other signs or symptoms of cardiovascular, respiratory, metabolic, immune, psychiatric, or musculoskeletal disease or disorders - Willingness to maintain consistent sleep duration the evening before study visits - Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, and carry out all study-related procedures - Able to complete a peak oxygen consumption exercise test with no contraindications to perform exercise per standards put forth by the American College of Sports Medicine. In other words, they are able to safety complete maximal exercise. Exclusion Criteria: - Positive medical history and/or is currently being treated for some form of heart disease, cardiovascular disease - Currently being treated for kidney disease, renal failure, or has dialysis performed on regular intervals - Has liver disease or some form of clinically diagnosed hepatic impairment - Diagnosed with having Type I or Type II diabetes (determined as fasting blood glucose > 126 mg/dL) - Diagnosed with or is being treated for some form of thyroid disease - Diagnosed with major affective disorder or other psychiatric disorder that required hospitalization in the prior year - Diagnosed with some form of immune disorder (i.e., HIV/AIDS) - History of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit). - Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea) - Positive medical history for any neurological condition or neurological disease - Currently prescribed a statin drugs (i.e., Lipitor, Livalo, Crestor, Zocor, etc.) or any hypertension medications (i.e., Beta-blockers, ACE Inhibitors, Alpha blockers, Vasodilators, etc.) - Current smoker (average of > 1 pack per day within the past 3 months) has quit within the past six months. This includes all forms of nicotine - Intake of any drugs (prescribed or over the counter) or dietary supplements that are known or are purported to weight loss such as thermogenics, hydroxycitric acid, ephedra, capsaicin, etc. - Participants who are lactating, pregnant or planning to become pregnant - Have a known sensitivity or allergy to any of the study products - History of alcohol or substance abuse in the 12 months prior to screening - Receipt or use of an investigational product in another research study within 30 days of beginning the study protocol - They plan major changes in lifestyle (i.e., diet, dieting, exercise level, travel, etc.) during the study - Recent history (<3 months) of exercise training or weight loss (> 5%) - Any orthopedic limitation that would prevent participation in a general fitness program - Any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data

Study Design


Intervention

Behavioral:
Exercise
12 week resistance and cardiovascular exercise program

Locations

Country Name City State
United States Exercise and Performance Nutrition Laboratory Saint Charles Missouri

Sponsors (1)

Lead Sponsor Collaborator
Lindenwood University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Fat Mass (4-compartment) Changes in Fat Mass (4-compartment) 12 weeks
Secondary 4-Compartment Lean mass Changes in Lean Mass (4-compartment) 12 weeks
Secondary Waist circumference Changes in Waist circumference 12 weeks
Secondary Visceral Fat (DEXA) Changes in Visceral Fat (DEXA) 12 weeks
Secondary Lean:Fat Ratio (DEXA) Changes in Lean:Fat Ratio (DEXA) 12 weeks
Secondary Body Mass Changes in Body Mass 12 weeks
Secondary Hunger and appetite visual analog scale Changes in Hunger and appetite visual analog scale 12 weeks
Secondary Profile of mood states (POMS) Changes in Profile of mood states (POMS) 12 weeks
Secondary Inflammatory markers (e.g. CRP, IL-6, etc.) Changes in Inflammatory markers (e.g. CRP, IL-6, etc.) 12 weeks
Secondary Comprehensive Metabolic Panel Changes in Comprehensive Metabolic Panel 12 weeks
Secondary Lipid Panel Changes in Lipid Panel 12 weeks
Secondary Self-reported adverse events Occurrences of Self-reported adverse events 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2